Bristol Myers Squibb’s (NYSE: BMY) Sotyktu (deucravacitinib) is continuing to vindicate the company’s decision to favor the drug’s development over Otezla (apremilast).
BMS acquired Sotyktu in its acquisition of Celgene in 2019 for $74 million, and opted to keep it rather than already-approved Otezla which, because of competition issues, was sold on to Amgen (Nasdaq: AMGN) for $13.4 billion.
"The first once-daily oral option to provide significant symptom relief"Sotyktu has since won approval in the USA for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze